NeuroVive furthers development of HCC, NASH inhibitors

NeuroVive announced two research agreements designed to further develop the company’s new drug compounds in the pipeline for the treatment of nonalcoholic steatohepatitis and hepatocellular carcinoma, according to a press release.

Philipe Gallay, PhD, will collaborate with the company to explore its novel sanglifehrin-based compounds which have shown potent inhibitory effects on HCC cells and anti-cancer activity in an experimental model of HCC.

Massimo Pinzani, MD, PhD, FRCP, will collaborate with the company to explore its NV556 project for the treatment of NASH. NV556 is a potent cyclophilin inhibitor that has shown an inhibitory effect on fibrosis development in an experimental model of NASH.

“I am very pleased that Philippe Gallay and Massimo Pinzani have joined our efforts in advancing the research and development of our NASH and HCC treatment opportunities,” Magnus Hansson, chief medical officer at NeuroVive, said in the release. “Their scientific guidance as experts in the field of liver disease mechanisms and clinical management will be most valuable in the continued development of our project pipeline, as well as in the ultimate positioning of our candidate drugs in the future treatment landscape.”

Reference: www.neurovive.com